Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 18/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 7/20 | 1.00 |
| ▸ | MDH2 | P40926 | 4/20 | 1.00 |
| ▸ | MDH1 | P40925 | 2/20 | 1.00 |
| ▸ | EP300 | Q09472 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721636 | 1.00 | HIF1A (1.00) | HIF1AEPAS1MDH2MDH1EP300 | |
| SCHEMBL2721120 | 0.91 | HIF1A (0.82) | HIF1AEPAS1MDH2MDH1EP300 | |
| SCHEMBL4301174 | 0.90 | HIF1A (1.00) | HIF1AEPAS1MDH2MDH1EP300 | |
| SCHEMBL4297027 | 0.89 | HIF1A (0.83) | HIF1AEPAS1MDH2MDH1EP300 | |
| SCHEMBL4299763 | 0.88 | HIF1A (0.79) | HIF1AEPAS1MDH2MDH1EP300 | |
| SCHEMBL4297100 | 0.88 | HIF1A (0.79) | HIF1AEPAS1MDH2MDH1EP300 | |
| SCHEMBL25633246 | 0.88 | HIF1A (0.78) | HIF1AEPAS1MDH2MDH1EP300 | |
| SCHEMBL4299489 | 0.84 | HIF1A (0.77) | HIF1AEPAS1MDH2MDH1EP300 | |
| SCHEMBL19269466 | 0.84 | HIF1A (0.73) | HIF1AEPAS1MDH2MDH1EP300 | |
| SCHEMBL21631152 | 0.84 | HIF1A (0.71) | HIF1AEPAS1MDH2MDH1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074989-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE | METANOIA BIO INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-20240269111-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240269124-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240262916-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4340836-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340896-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2022245711-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2022245697-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | disclosed |